Details of Disease

General Information of Disease (ID: DISFKT39)

• Disease Name: Diagnostic imaging
• Disease Class: N.A.: Diagnostic imaging
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISFKT39: Diagnostic imaging
• ICD Code: ICD-11: ICD-11: N.A.

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 15 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
14C-urea	DMLRYSQ	Approved	NA	[1]
Air polymer-type A	DM309J2	Approved	Ultrasound contrast agent	[2]
Chlormerodrin	DMSF4PR	Approved	Small molecular drug	[3]
Copper dotatate Cu-64	DM26KR1	Approved	Radioactive diagnostic agent	[4]
Florbetapir F-18	DMJ8A3Z	Approved	Small molecular drug	[5]
Fluorodopa F 18	DMRRPPW	Approved	Radioactive diagnostic agent	[6]
Ga-68-DOTATOC	DMZ0P95	Approved	radioactive diagnostic agent	[7]
Histamine Phosphate	DMV7IM6	Approved	Small molecular drug	[8]
Iodohippurate Sodium	DMTQKCR	Approved	Small molecular drug	[1]
Ovine corticotropin-releasing hormone	DME0F98	Approved	Small molecular drug	[1]
Pentagastrin	DMRCLZB	Approved	Small molecular drug	[9]
PSMA-11 Ga-68	DMWLTU2	Approved	Radioactive diagnostic agent	[10]
Selenomethionine Se-75	DMNUR1I	Approved	Small molecular drug	[1]
Xenon Xe-127	DM8IHME	Approved	Small molecular drug	[1]
Xenon Xe-133	DMIUK5W	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
(99M)-TC-CPI	DMBQXND	Phase 2	Small molecular drug	[11]
99mTc-RP-128	DMX2LO3	Phase 2	NA	[12]
Sprodiamide	DMNXZH1	Phase 1/2	Small molecular drug	[13]
99mTc-CYT-379	DMFKMEZ	Phase 1	NA	[14]
SR-4554	DMYRPBI	Phase 1	Small molecular drug	[15]
TECHNETIUM-99M-MRP20	DMI20YF	Phase 1	NA	[16]
[99MTC]-CBPAO	DMUNAT5	Phase 1	NA	[17]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
99mTc-nitrocade	DM3CVJX	Discontinued in Phase 3	NA	[18]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
99mTc-siboroxime	DMQOGOC	Investigative	NA	[19]
BMS-181321	DMXZZP0	Investigative	Small molecular drug	[19]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] Drug information of Chlormerodrin, 2008. eduDrugs.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [5] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [8] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 000734.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 870).
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [11] Technetium-99m isonitrile myocardial uptake at rest. I. Relation to severity of coronary artery stenosis. J Am Coll Cardiol. 1989 Dec;14(7):1673-7.
• [12] Evaluation of 99mTc-RP128 as a potential inflammation imaging agent: human dosimetry and first clinical results. J Nucl Med. 2001 Jan;42(1):154-61.
• [13] Permanent coronary artery occlusion: cardiovascular MR imaging is platform for percutaneous transendocardial delivery and assessment of gene therapy in canine model. Radiology. 2008 Nov;249(2):560-71.
• [14] The safety and pharmacokinetics in adult subjects of an intravenously administered 99mTc-labeled 17 amino acid peptide (CYT-379). Nucl Med Biol. 1994 Feb;21(2):131-42.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007525)
• [16] Technetium-99m-MRP20, a potential brain perfusion agent: in vivo biodistribution and SPECT studies in non-primate animals. J Nucl Med. 1991 Mar;32(3):500-5.
• [17] Evaluation of technetium 99m cyclobutylpropylene amine oxime as a potential brain perfusion imaging agent for SPET. Eur J Nucl Med. 1990;17(5):242-7.
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008008)
• [19] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.